Jamie Langton

Jamie Langton has a diverse and extensive work history. Their most recent role is as a Senior Research Scientist at Adrestia Therapeutics, where they are currently employed. Prior to this, Jamie worked as a Research Scientist at the same company.

Jamie's previous experience includes working as a Postdoctoral Research Associate at the University of Oxford from 2018 to 2020. In this role, they collaborated with AstraZeneca to study the synthetic lethal relationship between Poly (ADP-ribose) polymerases (PARPs) and cancer susceptibility genes. They utilized CRISPR gene editing to design cell lines that allowed for conditional depletion of target proteins and performed further gene editing to delete genes involved in synthetic lethality.

Before their postdoctoral position, Jamie was a DPhil Candidate at the University of Oxford from 2015 to 2018. During this time, they demonstrated the requirement of the Fanconi anaemia pathway in preventing genomic instability and developed CRISPR knock-out cell lines. They also investigated potential synthetic lethal relationships through RNAi.

Prior to their academic work, Jamie gained experience as a Research Technician at the University of Oxford in 2014 and as a Laboratory Assistant at Syntaxin Ltd in 2011.

Jamie also has non-research experience, having worked as an Accounts Team Leader at Specsavers from 2008 to 2010. In this role, they were responsible for managing a team of administrators, meeting financial deadlines, and fostering good working relationships across different locations.

Jamie Langton obtained a Bachelor of Science (BSc) degree in Zoology/Animal Biology from the University of Derby between 2005 and 2008. Following that, between 2012 and 2013, they pursued a Master of Science (MSc) degree in Molecular Medicine at The University of Sheffield. Lastly, Jamie completed their education by earning a Doctor of Philosophy (Ph.D.) in Oncology from the University of Oxford, studying from 2014 to 2019.